Overall, 78 (77.2%) patients needed additional immunohistochemical staining, particularly for CgA, Syn, CDX2, and CK, to confirm the neuroendocrine origin of the tumors and to detect the primary tumor site in those considered occult at initial diagnosis. The gene discussed is CDX2; the disease is neoplasm.